Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

NKTR
Nektar Therapeutics
stock NASDAQ

At Close
Jun 12, 2025 3:59:30 PM EDT
8.75USD-8.377%(-0.80)454,005
8.76Bid   8.78Ask   0.02Spread
Pre-market
Jun 12, 2025 9:08:30 AM EDT
9.54USD-0.105%(-0.01)650
After-hours
Jun 12, 2025 4:42:30 PM EDT
8.71USD-0.503%(-0.04)2,170
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 5, 2022
09:03AM EST  Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 40th   PR Newswire
Dec 31, 2021
01:14PM EST  Nektar Therapeutics Option Alert: May 20 $25 Calls at the Ask: 280 @ $1.3 vs 136 OI; Earnings 2/24 After Close [est] Ref=$13.7   Benzinga
Dec 15, 2021
09:44AM EST  Nektar Therapeutics (NKTR) said that proof-of-concept data presented by its partner Eli Lilly & Co. showed that, in patients with moderate to severe atopic dermatitis, NKTR-358 (LY3471851) given every two weeks over a 12-week period resulted in a dose-dependent reduction in EASI scores.   RTTNews
09:11AM EST  Nektar Therapeutics Announces Phase 1b Data For Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) In Patients With Atopic Dermatitis   Benzinga
09:10AM EST  Nektar Therapeutics Announces Phase 1b Data for Novel T Regulatory Cell   PR Newswire
08:03AM EST  Exelixis Announces Initiation Of Phase 1b Trial Evaluating XL092 In Combination With Immuno-oncology Therapies In Patients With Advanced Solid Tumors   Benzinga
Dec 13, 2021
09:06AM EST  Nektar Therapeutics Presents Clinical Data For NKTR-255 In Patients With Relapsed/Refractory Hematologic Malignancies, Including Patients With Prior CAR-T Therapy At ASH 2021   Benzinga
09:05AM EST  Nektar Therapeutics Presents Data For NKTR-255 In Patients With Relapsed/Refractory Hematologic Malignancies   RTTNews
09:02AM EST  Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, at the 63rd American Society of Hematology (ASH) Annual Meeting   PR Newswire
Dec 6, 2021
06:07AM EST  The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More   Benzinga
Dec 3, 2021
07:52PM EST  Signature Bank, SolarEdge Technologies and FactSet Research Systems Set to Join   PR Newswire
Nov 30, 2021
08:05AM EST  Nektar Therapeutics Announces Data Presentations For Its Immuno-Oncology Programs   RTTNews
08:02AM EST  Programs at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021 and the 63rd American Society of Hematology (ASH) Annual Meeting   PR Newswire
Nov 15, 2021
08:33AM EST  Nektar Therapeutics Appoints Diana Brainard As Independent Director To Board   RTTNews
08:31AM EST  Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M.   PR Newswire
Nov 12, 2021
07:20AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Alector, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:20AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:18AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:17AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:16AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:15AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:14AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:12AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:10AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Corvus, MiNK, Oncorus, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:09AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Corvus, MiNK, Oncorus, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:03AM EST  Nektar Announces Data Presentations For Its Immuno-Oncology Pipeline At The 2021 Society For Immunotherapy Of Cancer   RTTNews
07:01AM EST  Pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting   PR Newswire
Nov 10, 2021
08:23AM EST  The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance   Benzinga
Nov 9, 2021
08:15AM EST  with Cancer Specialist During 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting   PR Newswire
Nov 8, 2021
11:18AM EST  UPDATE: SVB Leerink On Nektar Price Target Cut: Believes 'Likelihood Of Failure For Bempeg In Lead Indications Is Higher Than Typical For Phase 3 Trials'; Remains Positive On Partnership Terms Of Bristol-Myers Deal As Co. Retains 65% Of Profits   Benzinga
09:06AM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021   Benzinga
08:29AM EST  The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More   Benzinga
07:42AM EST  Benchmark Upgrades Nektar Therapeutics to Buy, Announces $20 Price Target   Benzinga
06:33AM EST  SVB Leerink Maintains Market Perform on Nektar Therapeutics, Lowers Price Target to $18   Benzinga
Nov 5, 2021
09:48AM EDT  Oppenheimer Maintains Perform on Nektar Therapeutics, Lowers Price Target to $21   Benzinga
09:33AM EDT  Nektar Therapeutics Q3 EPS $(0.70) Beats $(0.80) Estimate, Sales $24.92M Miss $27.87M Estimate   Benzinga
09:30AM EDT  Nektar Therapeutics: Q3 Earnings Insights   Benzinga
Nov 4, 2021
04:28PM EDT  Nektar Therapeutics Q3 Loss/share $0.70 Vs. Loss $0.61 Year Ago   RTTNews
04:15PM EDT  Nektar Therapeutics Reports Third Quarter 2021 Financial Results   PR Newswire
08:19AM EDT  The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO   Benzinga
05:00AM EDT  Earnings Scheduled For November 4, 2021   Benzinga
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 26, 2021
06:00PM EDT  Nektar to Announce Financial Results for the Third Quarter 2021 on Thursday,   PR Newswire
Oct 12, 2021
08:18AM EDT  Nektar Therapeutics US Patent & Trademark Office Abstract Showing Patent Grant For Co.'s 'Method of making a water-soluble polymer-factor VIII moiety conjugate'   Benzinga
Oct 6, 2021
03:54PM EDT  Nektar Therapeutics Option Alert: Nov 19 $25 Calls at the Ask: 4950 @ $0.5 vs 912 OI; Earnings 11/4 After Close [est] Ref=$16.04   Benzinga
Sep 21, 2021
09:28AM EDT  Nektar Therapeutics (NKTR) has partnered with Merck KGaA and Pfizer Inc. to evaluate the combination of NKTR-255 with avelumab in urothelial carcinoma. Under the collaboration, Merck and Pfizer will include the combination of NKTR-255 plus avelumab in the new JAVELIN Bladder Medley study. Nektar will supply NKTR-255 for the trial.   RTTNews
09:08AM EDT  Nektar Collaborates With Merck KGaA And Pfizer To Combine NKTR-255 With Avelumab In JAVELIN Bladder Medley Study   RTTNews
09:03AM EDT  and Pfizer Inc. to Combine NKTR-255, a Novel Interleukin-15 Agonist, with Avelumab in the JAVELIN Bladder Medley Study   PR Newswire
09:03AM EDT  Nektar Therapeutics Reports New Clinical Collab With Merck In Germany, Pfizer To Combine NKTR-255 With Avelumab In JAVELIN Bladder Medley Study   Benzinga
Sep 10, 2021
07:36PM EDT  B of A Securities Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $18   Benzinga
Sep 2, 2021
11:31AM EDT  How Bad Are Nektar Therapeutics's Earnings? | Return on Capital Employed   Benzinga
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 12, 2021
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
Aug 10, 2021
07:55AM EDT  The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts   Benzinga
Aug 6, 2021
09:21AM EDT  SVB Leerink Maintains Market Perform on Nektar Therapeutics, Lowers Price Target to $19   Benzinga
Aug 5, 2021
06:00PM EDT  Nektar Therapeutics Q2 EPS $(0.69) Beats $(0.74) Estimate, Sales $28.33M Beat $25.98M Estimate   Benzinga
04:17PM EDT  Nektar Therapeutics Q2 Loss/share $0.69 Vs. Loss $0.45 Year Ago   RTTNews
04:15PM EDT  Nektar Therapeutics Reports Second Quarter 2021 Financial Results   PR Newswire
04:08AM EDT  Earnings Scheduled For August 5, 2021   Benzinga
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Jul 27, 2021
06:00PM EDT  Nektar to Announce Financial Results for the Second Quarter 2021 on Thursday,   PR Newswire
Jul 21, 2021
08:10AM EDT  Nektar Therapeutics Posts Study Titled 'BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)' To ClinicalTrials.Gov   Benzinga
Jul 19, 2021
09:02AM EDT  Nektar Appoints Dimitry Nuyten As SVP And Chief Medical Officer   RTTNews
09:02AM EDT  Nektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and   PR Newswire
Jul 8, 2021
10:13AM EDT  Nektar Therapeutics ClinicalTrials.gov Study Record Detail For Co.'s 'A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214)...'   Benzinga
Jun 28, 2021
10:21AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2021   Benzinga
05:42AM EDT  Stifel Upgrades Nektar Therapeutics to Buy, Raises Price Target to $24   Benzinga
Jun 14, 2021
08:34AM EDT  Exelixis Inc. (EXEL) said Monday that it has reached a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Co. (BMY) for STELLAR-002, a new phase 1b trial evaluating XL092 in combination with immuno-oncology therapies in advanced solid tumors.   RTTNews
Jun 7, 2021
08:31AM EDT  Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd   PR Newswire
May 20, 2021
11:04AM EDT  Nektar Publishes NKTR-358, Molecule Designed To Selectively Stimulate Expansion And Selective Function Of Treg Cells   RTTNews
11:02AM EDT  UPDATE: Nektar Highlights 'NKTR-358 Elicited Sustained and Preferential Proliferation of Regulatory T Cells Without Corresponding Effects on T Effector Cells in Preclinical Models'   Benzinga
11:01AM EDT  Nektar Therapeutics Highlights First Publication Of NKTR-358, a Novel Molecule Designed to Selectively Stimulate Expansion and Selective Function of T Regulatory Cells, in the Journal of Translational Autoimmunity   Benzinga
11:01AM EDT  Designed to Selectively Stimulate Expansion and Selective Function of T Regulatory Cells, in the Journal of Translational Autoimmunity   PR Newswire
May 18, 2021
08:05AM EDT  Nektar Therapeutics Highlights First Publication Of Preclinical Data On Anti-Tumor Properties Of IL-15 Agonist In Journal For ImmunoTherapy Of Cancer   Benzinga
08:05AM EDT  Nektar Therapeutics Publishes Preclinical Data Of IL-15 Agonist, NKTR-255, In The Journal For ImmunoTherapy Of Cancer   RTTNews
08:02AM EDT  Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC)   PR Newswire
May 10, 2021
06:19AM EDT  SVB Leerink Maintains Market Perform on Nektar Therapeutics, Lowers Price Target to $20   Benzinga
May 6, 2021
05:38PM EDT  Nektar Therapeutics Q1 EPS $(0.68) Beats $(0.72) Estimate, Sales $23.60M Miss $26.90M Estimate   Benzinga
04:16PM EDT  Nektar Therapeutics Q1 Loss/Shr $0.68 Vs Loss $0.78 Last Year   RTTNews
04:15PM EDT  Nektar Therapeutics Reports First Quarter 2021 Financial Results   PR Newswire
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
04:17AM EDT  Earnings Scheduled For May 6, 2021   Benzinga
Apr 27, 2021
06:00PM EDT  Nektar to Announce Financial Results for the First Quarter 2021 on Thursday,   PR Newswire
Apr 6, 2021
07:45AM EDT  SVB Leerink Maintains Market Perform on Nektar Therapeutics, Raises Price Target to $21   Benzinga
Feb 25, 2021
05:32PM EST  Nektar Therapeutics Q4 EPS $(0.65) Beats $(0.68) Estimate, Sales $23.46M Miss $30.01M Estimate   Benzinga
05:10PM EST  Nektar Therapeutics: Q4 Earnings Insights   Benzinga
04:25PM EST  Nektar Therapeutics Q4 Loss/share $0.65 Vs. Loss $0.64 Year Ago   RTTNews
04:25PM EST  Nektar Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results   PR Newswire
08:08AM EST  The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants   Benzinga
04:03AM EST  Earnings Scheduled For February 25, 2021   Benzinga
Feb 22, 2021
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2021   Benzinga
07:56AM EST  Benchmark Downgrades Nektar Therapeutics to Hold, Announces $26 Price Target   Benzinga
Feb 18, 2021
05:30PM EST  Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020   PR Newswire
08:14AM EST  The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout   Benzinga
Feb 17, 2021
10:41AM EST  Stock Alert: Nektar Therapeutics Up 13% On Collaboration   RTTNews
09:25AM EST  Nektar Therapeutics Secures $150M From SFJ Pharma For New Study With BEMPEG/Pembrolizumab Combo In Head & Neck Cancer   Benzinga
08:32AM EST  Nektar Therapeutics (NKTR) said that it has reached a financing and co-development collaboration with SFJ Pharmaceuticals to support the development of Bempegaldesleukin or BEMPEG, an investigational CD122-preferential IL-2-pathway agonist.   RTTNews
08:12AM EST  Nektar Announces Agreement For Phase 2/3 Study Of Bempegaldesleukin In Combination With KEYTRUDA   RTTNews
08:11AM EST  Nektar Announces Collaboration With SFJ Pharma To Support Development Of Bempegaldesleukin In Head And Neck Cancer   RTTNews
08:03AM EST  Nektar Announces Collaboration With SFJ Pharmaceuticals For Bempegaldesleukin In Head And Neck Cancer; Collaboration Supports Development Of Bempegaldesleukin, SFJ To Fund Up to $150M   Benzinga
08:03AM EST  Bempegaldesleukin, in Combination with Merck's KEYTRUDA(r) (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN)   PR Newswire
07:59AM EST  Nektar Announces Collaboration with SFJ Pharmaceuticals(r) for   PR Newswire
Jan 6, 2021
05:01PM EST  Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th   PR Newswire
10:14AM EST  Benzinga's Top Upgrades, Downgrades For January 6, 2021   Benzinga
07:31AM EST  The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping   Benzinga
07:16AM EST  Stifel Initiates Coverage On Nektar Therapeutics with Hold Rating, Announces Price Target of $18   Benzinga
Jan 5, 2021
04:22PM EST  Nektar Appoints Brian Kotzin As Interim Chief Medical Officer And Head Of Development   RTTNews
04:22PM EST  Nektar Appoints Dr. Brian Kotzin As Interim Chief Medical Officer   Benzinga
04:20PM EST  Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of   PR Newswire
Dec 22, 2020
08:36AM EST  Nektar Therapeutics Announces Agreement With Healthcare Royalty To Sell ADYNOVATE And MOVANTIK Royalties For $150M   Benzinga
08:32AM EST  Nektar Therapeutics Enters Agreement With Healthcare Royalty To Sell ADYNOVATE And MOVANTIK Royalties For $150 Mln   RTTNews
08:31AM EST  Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell   PR Newswire
Dec 15, 2020
08:32AM EST  Nektar Therapeutics Says First Patient Dosed In Phase 1/2 Trial Of NKTR-255   RTTNews
08:31AM EST  Nektar Therapeutics Reports Dosing Of First Patients In Phase 1/2 Study Of IL-15 Agonist, NKTR-255, In Combo With Cetuximab In Patients with Head and Neck Squamous Cell Carcinoma or Colorectal Cancer   Benzinga
08:31AM EST  its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma or Colorectal Cancer   PR Newswire
Dec 8, 2020
06:00AM EST  National law firm Barr Law Group is investigating the actions of the officers and board of directors of EQT Corporation, Zynerba Pharmaceuticals, Inc., Nektar Therapeutics, and Fiduciary/Claymore Energy Infrastructure Fund. If you are a current owner of shares of any of these stocks, contact leo@barrlaw.com or call (619) 400-4966.   GlobeNewswire Inc
Dec 7, 2020
04:01PM EST  its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting   PR Newswire
Nov 24, 2020
12:02PM EST  Watching Nektar Therapeutics Shares; US Patent & Trademark Office Abstract For Co.'s 'Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine'   Benzinga
Nov 12, 2020
10:12AM EST  SVB Leerink Maintains Market Perform on Nektar Therapeutics, Raises Price Target to $20   Benzinga
08:01AM EST  08:01 Thursday, November 12, 2020William Blair (RTTNews) - William Blair Reiterates Nektar Therapeutics (NKTR) At Outperform   RTTNews
Nov 11, 2020
02:01PM EST  Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the   PR Newswire
07:38AM EST  The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap   Benzinga
Nov 9, 2020
08:38AM EST  Nektar Therapeutics To Host Webcast Conference Call For Analysts & Investors With Expert Oncologist Panel During 2020 Society For Immunotherapy Of Cancer (SITC) 35th Annual Meeting   Benzinga
08:01AM EST  with Expert Oncologist Panel During 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting   PR Newswire
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 5, 2020
05:48PM EST  Nektar Therapeutics Q3 EPS $(0.61) Beats $(0.74) Estimate, Sales $30.03M Beat $26.33M Estimate   Benzinga
04:18PM EST  Nektar Therapeutics Q3 Loss/Shr $0.61 Vs $0.56 Last Year   RTTNews
04:16PM EST  Nektar Therapeutics Reports Third Quarter 2020 Financial Results   PR Newswire
07:54AM EST  The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping   Benzinga
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Nov 4, 2020
10:17AM EST  Nektar Therapeutics Reports Data Presented From Phase 1b Study Of NKTR-358 At 2020 American College Of Rheumatology Congress   Benzinga
10:15AM EST  Regulatory Cell Stimulator, at 2020 American College of Rheumatology (ACR) Congress   PR Newswire
Nov 1, 2020
09:40AM EST  The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings   Benzinga
Oct 29, 2020
06:00PM EDT  Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors   PR Newswire
Oct 28, 2020
06:00PM EDT  Nektar to Announce Financial Results for the Third Quarter 2020 on Thursday,   PR Newswire
Oct 27, 2020
07:46AM EDT  Nektar Therapeutics Reports Phase 1b Study To Evaluate Bempegaldesleukin For Treatment Of Patients Diagnosed With Mild COVID-19   Benzinga
07:34AM EDT  Nektar Therapeutics Received FDA Clearance For IND Application For Investigational IL-2 Pathway Agent, Bempegaldesleukin   RTTNews
07:31AM EDT  Bempegaldesleukin for Treatment of Patients Diagnosed with Mild COVID-19   PR Newswire
Aug 14, 2020
06:57AM EDT  SVB Leerink Maintains Market Perform on Nektar Therapeutics, Lowers Price Target to $17   Benzinga
Aug 12, 2020
08:16AM EDT  Vaccibody AS And Nektar Therapeutics Announce First Patient Dosed In Phase 1/2a Study Arm Evaluating VB10.NEO With Bempegaldesleukin In Patients With Squamous Cell Carcinoma Of The Head And Neck   Benzinga
08:07AM EDT  Vaccibody And Nektar Therapeutics Announce First Patient Dosed In Phase 1/2a Study Arm Evaluating VB10.NEO With NKTR-214   RTTNews
08:02AM EDT  1/2a Study Arm Evaluating VB10.NEO, a Personalized Neoantigen Cancer Vaccine, with Bempegaldesleukin (NKTR-214) in Patients with Squamous Cell Carcinoma of the Head and Neck   PR Newswire
Aug 6, 2020
05:36PM EDT  Nektar Therapeutics Q2 EPS $(0.45) Beats $(0.68) Estimate, Sales $48.40M My Not Compare To $22.80M Estimate   Benzinga
04:19PM EDT  Nektar Q2 Loss/Shr $0.45 Vs Loss $0.63 Last Year   RTTNews
04:16PM EDT  Nektar Therapeutics Reports Second Quarter 2020 Financial Results   PR Newswire
07:57AM EDT  The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO   Benzinga
Jul 28, 2020
06:00PM EDT  Nektar to Announce Financial Results for the Second Quarter 2020 on Thursday,   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC